Isobel Finnie

合伙人

UK and European Patent Attorney

Location
伦敦

About Isobel

Isobel leads the life sciences and biotechnology team at HLK, where her multi-disciplinary practice embraces a wide variety of life science technologies, especially in the fields of biotechnology and biochemistry. In the healthcare space she has developed considerable technical and professional expertise in the fields of cancer therapeutics and cancer pro-drugs, dermatology, biomarkers, diagnostics, vaccines, diabetes therapeutics, immunology, antibody-based therapeutics, stem cell technologies, DNA sequencing technologies and medical devices.

She is also known for expertise in foodstuffs and nutraceuticals, cosmetics and skin care products, household chemicals, biofuels and agricultural chemicals.

Isobel is a highly knowledgeable patent practitioner and patent strategist who has circa 20 years’ experience. She was a Partner at an Am Law 100 firm immediately prior to joining HLK, as well as having worked with other leading patent and trade mark firms in London, means clients value her analysis and input. She uses a collaborative approach to develop and implement IP strategies to support commercial requirements. Her strategic advice includes patent portfolio review, IP audits, IP due diligence, competitor IP analysis and freedom to operate (FTO) reviews, supplementary protection certificate (SPC) counselling and the preparation of Patent Attorney reports for IPOs. In addition, her practice involves patent drafting and international patent prosecution, working with complex patent portfolios of interrelated cases before the European Patent Office and post grant opposition and appeal proceedings.

Read more
Qualifications

MBiochem Biochemistry (University of Bath)
European Patent Attorney
EUIPO Representative
Intellectual Property Litigation Certificate
UK Patent Attorney

What clients say about Isobel:
I have worked with Isobel for over 10 years and found her blend of professionalism, subject knowledge and approachability an excellent combination for the smooth running of complex IP portfolios.
— Catherine Cawley, KCI An Acelity Company